Zosano Pharma (ZSAN) to Release Quarterly Earnings on Tuesday

Zosano Pharma (NASDAQ:ZSAN) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, May 14th.

Zosano Pharma (NASDAQ:ZSAN) last posted its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.85) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.16). On average, analysts expect Zosano Pharma to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

NASDAQ:ZSAN traded down $0.03 during trading hours on Thursday, hitting $3.39. The stock had a trading volume of 200 shares, compared to its average volume of 1,759,932. Zosano Pharma has a 1-year low of $1.85 and a 1-year high of $6.65. The company has a market capitalization of $58.05 million, a price-to-earnings ratio of -0.90 and a beta of 2.62.

In related news, CEO John Peter Walker purchased 100,000 shares of the firm’s stock in a transaction dated Thursday, April 11th. The stock was acquired at an average price of $3.50 per share, with a total value of $350,000.00. Following the completion of the transaction, the chief executive officer now owns 280,228 shares of the company’s stock, valued at $980,798. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.71% of the stock is currently owned by company insiders.

ZSAN has been the subject of several recent research reports. Maxim Group initiated coverage on shares of Zosano Pharma in a research report on Wednesday, April 17th. They issued a “buy” rating and a $8.00 price objective for the company. ValuEngine raised shares of Zosano Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, April 4th. Finally, Cantor Fitzgerald initiated coverage on shares of Zosano Pharma in a research report on Monday, April 22nd. They issued an “overweight” rating and a $3.66 price objective for the company.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2019/05/09/zosano-pharma-zsan-to-release-quarterly-earnings-on-tuesday.html.

About Zosano Pharma

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.

Featured Story: Momentum Indicators

Earnings History for Zosano Pharma (NASDAQ:ZSAN)

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply